Not sure if anyone else saw the annual results posted to sedar, but the revenue for the quarter backs out at $249k on the product side, a much number than quarters past.  Gross margin for the quarter was 61% if you ignore the services revenues, and given that they're just in start-up mode, there should be room for improvement there.  Bear in mind that I'm backing these numbers out of the annuals provided.  The net loss of $327k is also the lowest its been in at least 8 quarters (as far back as I've looked) and that should continue to shrink as sales ramp - they're expensing R&D that they're getting funded for of course...

Still waiting on an update regarding Teva's second order, with lots of news to come in the first quarter of 2013.  Buy while it's cheap!